Browsing by Author Hersey, Peter

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 84  next >
Issue DateTitleAuthor(s)Citation
2005Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma.Bron, L; Lee, Cheok; Palmer, Allan; Scolyer, Richard; Thompson, John; Hersey, Peter; McCarthy, S; Zhang, X. D.; Zhuang, L.; Central Clinical School: Medicine; Central Clinical School: Medicine; Medicine; Central Clinical School: Pathology; Central Clinical School: SurgeryActivation of the extracellular signal regulated kinase (ERK) pathway in human melanoma., Journal of Clinical Pathology 2005, vol.58,(11),2005,pp 1163-1169
2011Adaptation to ER Stress as a Mechanism of Resistance of Melanoma to TreatmentHersey, Peter; Dong, Li; Jiang, Chen Chen; Tay, Kwang Hong; Tseng, Hsin-Yi; Zhang, Xu Dong; Northern Clinical School: SurgeryAdaptation to ER Stress as a Mechanism of Resistance of Melanoma to Treatment in Current Management of Malignant Melanoma, InTech Publishers, 2011, pp. 253-274
2002Adjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized TrialCoates, Alan; McCarthy, William; McMullen, A V E; Simes, Robert John; Thompson, John; Coventry,, B; Dillon, H; Grantley, G l; Hersey, Peter; Mcleod,, R; Sillar, R; School of Public Health: Public Health; Central Clinical School: Surgery; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: SurgeryAdjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial, Journal of Clinical Oncology, vol.20,(20),2002,pp 4181-4189
2010Apoptosis of Human Melanoma Cells Induced by Inhibition of B-RAFV600E Involves Preferential Splicing of BimSBecker, Therese; Rizos, Helen; Croft, A.; Hersey, Peter; Jiang, Chen Chen; Lai, F; Liu, H.; Tay, KH; Thorne, R F; Yang, F.; Zhang, Xu Dong; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteApoptosis of Human Melanoma Cells Induced by Inhibition of B-RAFV600E Involves Preferential Splicing of BimS, Cell Death & Disease, vol.1, 9,pp e69-1-e69-14
2016Association of pembrolizumab with tumor response and survival among patients with advanced melanomaHersey, Peter; Daud, Adil; et al, Various; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joshua, Anthony M.; Kefford, Richard F; Patnaik, Amita; Ribas, Antoni; Wolchok, Jedd D.; Northern Clinical School: SurgeryAssociation of pembrolizumab with tumor response and survival among patients with advanced melanoma, JAMA: The Journal of the American Medical Association, vol.315, 15, 2016,pp 1600-1609
2006Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group.Millward, Michael; Bedikian, Agop Y.; Conry, Robert; DeConti, Ronald; Gore, Martin; Haluska, Frank G.; Hersey, Peter; Hersh, Evan M.; Kirkwood, John M; Pavlick, Anna C.; Pehamberger, Hubert; Trefzer, Uwe; MedicineBcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group., JOURNAL OF CLINICAL ONCOLOGY 2005, vol.24,(29),2006,pp 4738-4745
2013The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistanceGallagher, Stuart; Haass, Nikolas; Hersey, Peter; Mijatov, Branka; Lai, Fritz; Mohana-Kumara, Nethia; Wroblewski, David; Zhang, Xu Dong; Western Clinical School: Medicine (Westmead); Central Clinical School: Centenary Institute; Northern Clinical School: Surgery; Western Clinical School: Westmead Millennium InstituteThe BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance, Carcinogenesis, vol.34, 2, 2013,pp 237-247
2013BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III MelanomaCampain, Anna; Carter, Candace; De Silva, Chitra; Gerega, Sebastien; Hersey, Peter; Kefford, Richard (Rick); Lai, Kenneth; Mann, Graham; Pianova, Svetlana; Pupo, Gulietta; Schramm, Sarah-Jane; Scolyer, Richard; Synnott, Catherine; Thompson, John; Wilmott, James; Yang, Yee (Jean); Mathematics & Statistics; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Melanoma Foundation; Biological Sciences; Northern Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Clinical Ophthal & Eye Health; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Central Clinical School: Pathology; RADS - Research Analytics & Data Strategy; Central Clinical School: Surgery; Central Clinical School: Surgery; Mathematics & StatisticsBRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma, The Journal of Investigative Dermatology, vol.133, 2, 2013,pp 509-517
2018CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 TreatmentBritton, Warwick; Chen, Jinbiao; Edwards, Jarem; Ferguson, Angela; Gide, Tuba; Hersey, Peter; Hewavisenti, Rehana; Long, Georgina; Madore, Jason; Menzies, Alexander Maxwel; Palendira, Umaimainthan; Quek, Camelia; Saw, Robyn; Scolyer, Richard; Tasker, Annie; Thompson, John; Weninger, Wolfgang; Wilmott, James; Gebhardt, Thomas; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Medicine; Physiology; Northern Clinical School: Surgery; Veterinary Science; Northern Clinical School: Medicine; Central Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: Pathology; Charles Perkins Centre; Central Clinical School: Surgery; Central Clinical School: Centenary Institute; Central Clinical School: SurgeryCD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment, Clinical Cancer Research, vol.24, 13, 2018,pp 3036-3045
2008Chemoablation of metastatic melanoma using intralesional Rose BengalThompson, John; Hersey, Peter; Wachter, Eric; Central Clinical School: SurgeryChemoablation of metastatic melanoma using intralesional Rose Bengal, Melanoma Research: an international journal of rapid communications of basic and clinical research in melanoma, vol.18,(N/A),2008,pp 405-411
2015Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signalingDe Paoli-Iseppi, Ricardo; Gallagher, Stuart; Gowrishankar, Kavitha; Gunatilake, Dilini; Heinemann, Anja; Hersey, Peter; Madore, Jason; Strbenac, Dario; Tiffen, Jessamy; Wilmott, James; Yang, Jean Yee Hwa; Cullinane, Carleen; McArthur, Grant A.; Prinjha, Rab; Smithers, Nicholas; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Northern Clinical School: Surgery; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Mathematics & Statistics; Central Clinical School: Centenary Institute; Central Clinical School: Surgery; Mathematics & StatisticsCombining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling, Oncotarget, vol.6, 25, 2015,pp 21507-21521
2017Completion dissection or observation for sentinel-node metastasis in melanomaHersey, Peter; Nieweg, Omgo; Thompson, John; Andtbacka, R; Beitsch, P; Bowles, Tawnya; Cochran, Alistair; et al, Various; Faries, Mark B.; Jahkola, Tiina; Mozzillo, Nicola; Testori, Alessandro; Zager, Jonathan; Northern Clinical School: Surgery; Central Clinical School: Surgery; Central Clinical School: SurgeryCompletion dissection or observation for sentinel-node metastasis in melanoma, New England Journal of Medicine, vol.376, 23, 2017,pp 2211-2222
2014Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151Gallagher, Stuart; Gowrishankar, Kavitha; Gunatilake, Dilini; Hersey, Peter; Jin, Lei; Mijatov, Branka; Pupo, Gulietta; Rizos, Helen; Tiffen, Jessamy; Cullinane, Carleen; James, Wilmott; McArthur, Grant A.; Tummino, Peter J; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Northern Clinical School: Kolling Institute; Northern Clinical School: Surgery; Northern Clinical School: Kolling Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: Centenary InstituteControl of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151, Pigment Cell & Melanoma Research, vol.27, 6, 2014,pp 1126-1137
2013Cotargeting histone deactylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3Hersey, Peter; Atmadibrata, B; Chi, MN; Croft, A.; Farelly, M; Guo, Su T; Jiang, CC; Jin, Lei; Lai, F; Liu, T; Norman, J; Tseng, Hsin-Yi; Wang, CY; Zhang, XD; Northern Clinical School: SurgeryCotargeting histone deactylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3, Cell Death and Disease, vol.4, N/A, 2013,pp 1-13
2010Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cellsChristopherson, Richard; Yang, E.; Dong, L.; Hersey, Peter; Jiang, Chen Chen; Liu, H.; Tay, KH; Thorne, R F; Tseng, H-Y; Yang, F.; Zhang, Xu Dong; School of Molecular Bioscience; School of Molecular BioscienceCystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells, Cell Death & Differentiation, vol.17, 8,pp 1354-1367
2014Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanomaCarlino, Matteo; Fung, C.; Gowrishankar, Kavitha; Hersey, Peter; Kefford, Richard (Rick); Long, Georgina; Mijatov, Branka; Pupo, Gulietta; Rizos, Helen; Snoyman, Stephanie; Todd, Jason; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Northern Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteDifferential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma, Molecular Oncology, vol.8, 3, 2014,pp 544-554
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674